Johnson & Johnson reported a slight decline in revenue driven by currency effects and generic competition in the U.S., but operational sales increased by 3.5%. The company raised its full-year earnings guidance and expressed confidence in its strategic initiatives, including the Synthes integration and global expansion efforts. These factors are likely to generate a positive sentiment in the short term.

[1]